Human medicines European public assessment report (EPAR): Eptifibatide Accord, eptifibatide, Date of authorisation: 11/01/2016, Revision: 7, Status: Authorised

3 April 2025

Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

3 April 2025

Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Date of authorisation: 16/07/2021, Revision: 7, Status: Authorised

3 April 2025

Human medicines European public assessment report (EPAR): Copiktra, duvelisib, Date of authorisation: 19/05/2021, Revision: 3, Status: Authorised

3 April 2025

Scientific and technical recommendations: Veterinary Medicines Regulation

3 April 2025

Clinical Trials Information System designated as WHO primary registry

3 April 2025

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 18 February 2025, 09:30 (CET) to 18 February 2025, 13:00 (CET)

2 April 2025

Human medicines European public assessment report (EPAR): Extavia, interferon beta-1b, Date of authorisation: 20/05/2008, Revision: 26, Status: Authorised

2 April 2025

Human medicines European public assessment report (EPAR): Jardiance, empagliflozin, Date of authorisation: 22/05/2014, Revision: 31, Status: Authorised

2 April 2025

EMEA-002565-PIP02-19-M01

2 April 2025